Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ABACAVIR SULFATE; LAMIVUDINE

ABACAVIR SULFATE; LAMIVUDINE

Standard Dose
60MG; 30MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview ABACAVIR SULFATE; LAMIVUDINE is listed in Drugs@FDA under application 202381 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ABACAVIR SULFATE; LAMIVUDINE Form and strength TABLET; ORAL - 60MG; 30MG Sponsor MYLAN LABS Submission history Latest submission status date: 2012-01-31 00:00:00.

Structured Monograph

Clinical summary

Approval overview ABACAVIR SULFATE; LAMIVUDINE is listed in Drugs@FDA under application 202381 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ABACAVIR SULFATE; LAMIVUDINE Form and strength TABLET; ORAL - 60MG; 30MG Sponsor MYLAN LABS Submission history Latest submission status date: 2012-01-31 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.